CommercialCoverageHigh impact
Jaw Motion Rehabilitation Systems (CPB 0412, reviewed 2026-06-30)
Aetna·Oncology, Radiation Oncology, Oral & Maxillofacial Surgery +3 more·Medical Policy
Effective date
Jun 30, 2026
We identified it
Aug 14, 2026
Summary
Aetna's updated policy (effective 2026-06-30) narrows coverage for jaw motion rehabilitation systems to ONLY mandibular hypomobility caused by radiation in head and neck cancer patients. All other indications—including TMJ dysfunction, trismus, facial trauma, and stroke—are now classified as experimental/investigational and not covered. Billing teams must immediately identify claims for non-covered indications and either deny them or require prior authorization verification.
Action Required
By 2026-06-30: Billing team must update claims processing system to implement coverage rules: (1) ALLOW claims with HCPCS E1700, E1701, E1702 ONLY when diagnosis codes include C76.0 (head/neck malignancy), M26.69 (TMJ disorder), AND Z92.3 (history of irradiation); (2) DENY or require prior authorization for ALL other ICD-10 diagnoses listed as experimental, including R25.2 (trismus), G12.0-G12.9 (spinal muscular atrophy), G71.01 (Duchenne muscular dystrophy), I60-I69 (stroke/cerebrovascular disease), M26.03 (mandibular hyperplasia), Q75.4 (Treacher Collins), S00-S09 and T20 (burns/trauma); (3) Update claim scrubbing logic to flag claims combining E1700-E1702 with non-covered diagnoses for denial; (4) Train billing staff on the specific covered indication (radiation-induced mandibular hypomobility only) to catch coding errors before submission. Notify providers that pentoxifylline plus vitamin E is not covered for scleroderma-related trismus. Failure to implement will result in claim denials and potential overpayments requiring recovery.